Efficacy and Adverse Reactions of Sintillimab Combined with Pemetrexed and Cisplatin in the Treatment of Advanced Lung Adenocarcinoma
Objective:To study the efficacy and adverse reactions of sintillimab combined with pemetrexed and cisplatin in the treatment of advanced lung adenocarcinoma,so as to provide reference for clinical application.Methods:33 patients with advanced lung adenocarcinoma confirmed by pathology or cytology admitted to the hospital from March 2019 to November 2022 were selected as the study objects.They were randomly divided into 17 cases in study group and 16 cases in control group.The study group received sintillimab combined with AP regimen,and the control group received AP regimen.The short-term and long-term efficacy,and the incidence of adverse reactions were compared between the two groups.Results:ORR and DCR in the study group were higher than the control group,with statistically significant difference(P＜0.05).After treatment,serum CEA and CA125 levels in study group and control group decreased,and the decrease in the study group was higher than that in the control group,with statistically significant difference(t=-2.088,-2.060;P＜0.05).After treatment,the incidence of hypertension in study group was higher than that in control group,with statistically significant difference(P＜0.05).But there was no statistically significant difference in gastrointestinal reaction,bone marrow suppression,fever,fatigue,liver and kidney function,albuminuria,myalgia,oral ulcer and thyroid function(P＞0.05).Conclusion:Sintillimab combined with AP regimen has better efficacy than AP regimen in the treatment of advanced lung adenocarcinoma,with no significant increase in adverse reactions,which is worthy of clinical application.
万方数据
维普
